Mark Corrigan

Board Director

Director

Nabriva Therapeutics plcWave Life Sciences Ltd.Wave Life Sciences, Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 1 saleJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

138

Companies

▲ Purchases (0 ops.)

—

▼ Sales (104 ops.)

€8.3M

Latest filing published 07 Oct 2026 for WAVE LIFE SCIENCES, INC..

Filing timeline

BuySale

Mark Corrigan

Insider track record

Disclosed buys

Disclosed sells

104

Signal history

Mark Corrigan: trading record in brief

Mark Corrigan is a declared insider at 5 companies (board member); the most frequent names are Sepracor Inc /DE/, Cubist Pharmaceuticals Inc and EPIRUS Biopharmaceuticals, Inc. Over a trading history stretching from 16 March 2006 to 5 October 2026, the count stands at 138 filings.

No open-market purchase appears, only 104 sales worth €8.3M. The rest of the record consists of 23 share grants and 7 option exercises.

On 7 October 2026 came the latest disclosure, a share grant in Wave Life Sciences Ltd. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.